Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cue Biopharma

Current price
1.35 USD +0.01 USD (+0.75%)
Last closed 1.34 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 65 668 456 USD
Yield for 12 month -66.58 %
21.11.2021 - 28.11.2021

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Address: 40 Guest Street, Boston, MA, United States, 02135

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

9.4 USD

P/E ratio

Dividend Yield

Current Year

+5 490 000 USD

Last Year

+1 245 227 USD

Current Quarter

+1 717 000 USD

Last Quarter

+1 821 000 USD

Current Year

+2 054 000 USD

Last Year

-560 828 USD

Current Quarter

+868 000 USD

Last Quarter

+970 000 USD

Key Figures CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -50 802 000 USD
Operating Margin TTM -737.8 %
PE Ratio
Return On Assets TTM -47.26 %
PEG Ratio
Return On Equity TTM -117.5 %
Wall Street Target Price 9.4 USD
Revenue TTM 7 020 000 USD
Book Value 0.62 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 818.2 %
Dividend Yield
Gross Profit TTM 1 245 227 USD
Earnings per share -1.07 USD
Diluted Eps TTM -1.07 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CUE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 9.2569
Price Sales TTM 15.5056
Enterprise Value EBITDA -1.1035
Price Book MRQ 2.2823

Financials CUE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CUE

For 52 weeks

1.26 USD 4.89 USD
50 Day MA 1.66 USD
Shares Short Prior Month 4 590 371
200 Day MA 2.19 USD
Short Ratio 13.85
Shares Short 4 349 443
Short Percent 9.5 %

Dynamics of changes in the value of assets




446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds



203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics



2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics